Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 12:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 328 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Post-operative adjuvant therapy Clear all
Completed Phase 2 Interventional Results available

Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma

NCT02296684
View directory record Official record
Conditions
Cancer of Head and Neck, Head and Neck Cancer, Neoplasms, Head and Neck, Carcinoma, Squamous Cell of Head and Neck, Squamous Cell Carcinoma of the Head and Neck, Squamous Cell Carcinoma, Head and Neck
Interventions
MK-3475 (neoadjuvant), Surgery, Intensity modulated radiation therapy, Image-guided radiation therapy, Cisplatin, MK-3475 (adjuvant), Peripheral blood
Biological · Procedure · Radiation + 1 more
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
3
States / cities
Boston, Massachusetts • St Louis, Missouri • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Sep 17, 2026, 12:59 AM EDT
Terminated Early Phase 1 Interventional

Window of Opportunity Pilot Study of Pembrolizumab in Obesity-driven Endometrial Cancer

NCT03694834
View directory record Official record
Conditions
Endometrial Cancer, Uterine Cancer
Interventions
Pembrolizumab, Hysterectomy
Drug · Procedure
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 27, 2023 · Synced Sep 17, 2026, 12:59 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Prospective Randomized Double Blind Trial to Assess the Effect of a Single Preoperative Dose of Gabapentin on Postoperative Opioid Consumption in Patients Undergoing Rhinoplasty

NCT03498261
View directory record Official record
Conditions
Pain, Postoperative, Opioid Use
Interventions
Gabapentin, Placebos
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 10, 2025 · Synced Sep 17, 2026, 12:59 AM EDT
Recruiting Phase 2Phase 3 Interventional

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

NCT05987241
View directory record Official record
Conditions
Muscle Invasive Bladder Urothelial Carcinoma, Muscle Invasive Renal Pelvis Urothelial Carcinoma, Muscle Invasive Ureter Urothelial Carcinoma, Muscle Invasive Urethral Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma AJCC v6 and v7, Stage III Bladder Urothelial Carcinoma AJCC v6 and v7, Stage IV Bladder Urothelial Carcinoma AJCC v7
Interventions
Biospecimen Collection, cfDNA or ctDNA Measurement, Computed Tomography, Cystoscopy, Magnetic Resonance Imaging, Nivolumab, Questionnaire Administration, Relatlimab
Procedure · Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
992 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
491
States / cities
Phoenix, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 371 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Sep 17, 2026, 12:59 AM EDT
Terminated Phase 2 Interventional

Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma

NCT02225496
View directory record Official record
Conditions
Oropharyngeal Cancer
Interventions
Transoral Robotic Surgery (TORS), Modified Barium Swallow (MBS), Questionnaires
Procedure · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 14, 2017 · Synced Sep 17, 2026, 12:59 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)

NCT03765918
View directory record Official record
Conditions
Head and Neck Neoplasms
Interventions
Pembrolizumab 200 mg, Radiotherapy 60 Gray, Radiotherapy 66 Gray, Radiotherapy 70 Gray, Cisplatin 100 mg/m^2
Biological · Radiation · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
714 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
68
States / cities
La Jolla, California • Los Angeles, California • Newport Beach, California + 56 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 17, 2026, 12:59 AM EDT
Terminated Phase 3 Interventional

Stage IV Surgery Versus Best Medical Therapy

NCT01013623
View directory record Official record
Conditions
Stage IV Resectable Melanoma
Interventions
Surgery, Surgery plus 2 adjuvant doses of BCG, best medical therapy
Procedure · Other
Lead sponsor
Saint John's Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
15
States / cities
Sacramento, California • Santa Monica, California • Chicago, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2012 · Synced Sep 17, 2026, 12:59 AM EDT
Withdrawn Phase 2 Interventional

Clinical Trial Comparing 3-D RT vs. IMRT in Post- Prostatectomy Prostate Cancer Patients

NCT02678520
View directory record Official record
Conditions
Prostate Cancer
Interventions
3-D Conformal Radiation Therapy, Intensity Modulated Radiation Therapy, Casodex, Zoladex , Lupron
Radiation · Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Fairway, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 21, 2016 · Synced Sep 17, 2026, 12:59 AM EDT
Recruiting Early Phase 1 Interventional

Neoadjuvant Chemoradiotherapy With or Without Concurrent Azeliragon in Patients With Newly Diagnosed Glioblastoma

NCT06831526
View directory record Official record
Conditions
Glioblastoma
Interventions
Azeliragon, Temozolomide, Radiation therapy, Surgery or LITT
Drug · Radiation · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 17, 2026, 12:59 AM EDT
Recruiting Not applicable Interventional

ctDNA Testing to Inform Standard-of-Care Treatment Decisions in People With Endometrial Cancer

NCT07270666
View directory record Official record
Conditions
Endometrial Cancer
Interventions
ctDNA Testing, Blood draw, Surveys, Semi-structured interviews
Genetic · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 17, 2026, 12:59 AM EDT
Completed Phase 1 Interventional

A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab With or Without Ipilimumab in Patients With Ovarian Cancer

NCT03245892
View directory record Official record
Conditions
High Grade Serous Ovarian, Fallopian Tube, Primary Peritoneal Cancer
Interventions
Carboplatin and Paclitaxel, Nivolumab, Cytoreductive surgery, Ipilimumab
Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Sep 17, 2026, 12:59 AM EDT
Completed Phase 2 Interventional Results available

Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting

NCT00618657
View directory record Official record
Conditions
Breast Cancer, HER2-negative Breast Cancer, HER2-positive Breast Cancer, Recurrent Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
Carboplatin, paclitaxel albumin-stabilized nanoparticle formulation, bevacizumab, trastuzumab, magnetic resonance imaging, therapeutic conventional surgery
Drug · Procedure
Lead sponsor
University of California, Irvine
Other
Eligibility
21 Years to 90 Years · Female only
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2021
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Feb 27, 2024 · Synced Sep 17, 2026, 12:59 AM EDT
Completed Phase 1 Interventional

GMCI, Nivolumab, and Radiation Therapy in Treating Patients With Newly Diagnosed High-Grade Gliomas

NCT03576612
View directory record Official record
Conditions
Glioma, Malignant
Interventions
AdV-tk, Valacyclovir, Radiation, Temozolomide, Nivolumab, Laboratory Biomarker Analysis
Biological · Drug · Radiation + 1 more
Lead sponsor
Candel Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
5
States / cities
Boston, Massachusetts • Detroit, Michigan • Winston-Salem, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Sep 17, 2026, 12:59 AM EDT
Completed Phase 2 Interventional Results available

Irinotecan, Cisplatin, Bevacizumab, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Esophageal Cancer

NCT00354679
View directory record Official record
Conditions
Esophageal Cancer
Interventions
bevacizumab, cisplatin, irinotecan hydrochloride, proteomic profiling, diagnostic laboratory biomarker analysis, mass spectrometry, adjuvant therapy, neoadjuvant therapy, therapeutic conventional surgery, radiation therapy
Biological · Drug · Genetic + 3 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 15, 2016 · Synced Sep 17, 2026, 12:59 AM EDT
Recruiting Phase 2 Interventional

Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer

NCT07140679
View directory record Official record
Conditions
Localized Colon Carcinoma, Stage IIB Colon Cancer AJCC v8, Stage IIC Colon Cancer AJCC v8, Stage III Colon Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Colonoscopy, Computed Tomography, Questionnaire Administration, Toripalimab
Procedure · Other · Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
5
States / cities
Atlanta, Georgia • Johns Creek, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Sep 17, 2026, 12:59 AM EDT
Completed No phase listed Observational

Correlation of Menstrual Cycle Phase at Time of Primary Surgery With 5-Year Disease-Free Survival in Women With Stage I or Stage II Breast Cancer

NCT00002762
View directory record Official record
Conditions
Breast Cancer, Perioperative/Postoperative Complications
Interventions
patient interviewing to obtain menstrual history, blood sampling
Behavioral · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
1,118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2009
U.S. locations
52
States / cities
Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 44 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2016 · Synced Sep 17, 2026, 12:59 AM EDT
Recruiting Phase 1Phase 2 Interventional

Nisin in Oral Cavity Squamous Cell Carcinoma (OCSCC)

NCT06097468
View directory record Official record
Conditions
Oral Cavity Squamous Cell Carcinoma
Interventions
NisinZ® P, Surgery (non-interventional, standard of care)
Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 17, 2026, 12:59 AM EDT
Recruiting Not applicable Interventional

Multi-Site Trial of Navigation vs Treatment as Usual to Improve Initiation of Timely Adjuvant Therapy

NCT05793151
View directory record Official record
Conditions
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Oropharynx Cancer, Oral Cavity Cancer, Larynx Cancer
Interventions
ENDURE
Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
532 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
4
States / cities
St Louis, Missouri • Durham, North Carolina • Charleston, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Sep 17, 2026, 12:59 AM EDT
Active, not recruiting Phase 3 Interventional

Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)

NCT03725059
View directory record Official record
Conditions
Breast Cancer
Interventions
Pembrolizumab (K), Placebo (P), Paclitaxel (X), Doxorubicin (A), Epirubicin (E), Cyclophosphamide (C), Endocrine therapy, Radiation therapy, Surgery
Biological · Drug · Radiation + 1 more
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
1,240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2031
U.S. locations
45
States / cities
Daphne, Alabama • Goodyear, Arizona • Tucson, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2025 · Synced Sep 17, 2026, 12:59 AM EDT
Active, not recruiting Phase 3 Interventional

Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer

NCT04340141
View directory record Official record
Conditions
Pancreatic Adenosquamous Carcinoma, Resectable Pancreatic Adenocarcinoma, Stage I Pancreatic Cancer AJCC v8, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8
Interventions
Oxaliplatin, Irinotecan Hydrochloride, Leucovorin Calcium, Fluorouracil, Resection, Questionnaire Administration
Drug · Procedure · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
441
States / cities
Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 325 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 17, 2026, 12:59 AM EDT
Completed Phase 2 Interventional

Surgery With or Without Chemotherapy and Radiation Therapy in TreatingPatients With Stage I Rectal Cancer

NCT00023751
View directory record Official record
Conditions
Colorectal Cancer
Interventions
fluorouracil, leucovorin calcium, conventional surgery, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
178
States / cities
Anniston, Alabama • Mobile, Alabama • Phoenix, Arizona + 114 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2016 · Synced Sep 17, 2026, 12:59 AM EDT
Active, not recruiting Phase 3 Interventional

Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer

NCT06732401
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Ceralasertib, Computed Tomography, Durvalumab, Echocardiography Test
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
192
States / cities
Jonesboro, Arkansas • Beverly Hills, California • Los Angeles, California + 163 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 17, 2026, 12:59 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma

NCT03197506
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma, Supratentorial Glioblastoma
Interventions
External Beam Radiation Therapy, Laboratory Biomarker Analysis, Pembrolizumab, Radiation Therapy, Temozolomide, Therapeutic Conventional Surgery
Radiation · Other · Biological + 2 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
3
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Sep 17, 2026, 12:59 AM EDT
Active, not recruiting Phase 3 Interventional Results available

S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer

NCT00070564
View directory record Official record
Conditions
Breast Cancer
Interventions
pegfilgrastim, AC regimen, cyclophosphamide, doxorubicin hydrochloride, paclitaxel
Biological · Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
3,294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2027
U.S. locations
539
States / cities
Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 369 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 17, 2026, 12:59 AM EDT